Breast Cancer
From the Journals
Metastatic breast cancer lesions immunologically depleted compared with primary
In an analysis of the immune microenvironment of breast cancer tissue samples, metastatic breast cancer lesions were relatively inert compared...
From the Journals
Outcomes similar for concurrent versus sequential treatment in HER2-positive breast cancers
Long-term results of a phase 3 trial indicate that concurrent FEC, paclitaxel and trastuzumab is not warranted, investigators say.
Latest News
Top cancer researcher fails to disclose corporate financial ties in major research journals
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in...
Guidelines
ESMO scale offers guidance on cancer targets
The ESMO Scale of Clinical Actionability for Molecular Targets is intended to help oncologists prioritize therapeutic targets detected on gene...
From the Journals
Inherited mutations drive 12% of Nigerian breast cancer
Mutations in four breast cancer risk genes cause about one in eight cases of the malignancy in Nigerian women.
Community Translations
Neratinib extends adjuvant treatment of patients with HER2-positive breast cancer
New Therapies
Meeting the potential of immunotherapy: new targets provide rational combinations
From the Journals
Variants in five genes signal TNBC risk
Risks for triple-negative breast cancer associated with pathogenic variants in five genes ranged from about 5.5-fold to nearly 17-fold.
From the Journals
RT linked with better survival in DCIS
Lumpectomy plus radiotherapy is associated with a significant reduction in breast cancer mortality versus lumpectomy or mastectomy alone.
From the Journals
Herceptin linked to doubling of HF risk in women with breast cancer
Most patients are not receiving the frequency of guideline-recommended cardiac screening, study finds.
From the Journals
CTCs linked to late recurrence in HER2–, HR+ breast cancer
Study is the first to show that this CTC assay may play a role in determining late clinical recurrence after local and systemic adjuvant therapy...